Astrazeneca: new positive data for lung cancer
(CercleFinance.com) - The AstraZeneca share is up in London this morning, following the announcement of positive data in the Phase III PACIFIC trial for its Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell Stage III lung cancer (NSCLC).
The pharmaceutical group reports that in a planned interim analysis the trial has met its second of two primary endpoints by showing statistically-significant OS benefit with clinically-meaningful improvement in patients receiving Imfinzi compared to placebo.
A year ago, the group already reported having reached the trial primary endpoint, with a median increase of 11.2 months in the progression-free survival of the disease, compared with placebo.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The pharmaceutical group reports that in a planned interim analysis the trial has met its second of two primary endpoints by showing statistically-significant OS benefit with clinically-meaningful improvement in patients receiving Imfinzi compared to placebo.
A year ago, the group already reported having reached the trial primary endpoint, with a median increase of 11.2 months in the progression-free survival of the disease, compared with placebo.
Copyright (c) 2018 CercleFinance.com. All rights reserved.